QURE · Company research
uniQure N.V. (QURE): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
23records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| QURE Jumps 20% – Analysts Upgrade Stock On Huntington’s Disease Therapy Update, Retail Eyes $150 - Stocktwits | QURE Jumps 20% – Analysts Upgrade Stock On Huntington’s Disease Therapy Update, Retail Eyes $150 Stocktwits | View source ↗ | Stocktwits | Oct 17, 2026 | neutral | 0 | 0.6 |
| uniQure N.V. Ordinary Shares (QURE) Company Profile - Pluang | uniQure N.V. Ordinary Shares (QURE) Company Profile Pluang | View source ↗ | Pluang | Oct 17, 2026 | neutral | 0 | 0.6 |
| The Technical Signals Behind (QURE) That Institutions Follow - Stock Traders Daily | The Technical Signals Behind (QURE) That Institutions Follow Stock Traders Daily | View source ↗ | Stock Traders Daily | Oct 17, 2026 | neutral | 0 | 0.6 |
| JPMorgan Chase reports a passive stake in uniQure (QURE) through four subsidiaries. - Stock Titan | JPMorgan Chase reports a passive stake in uniQure (QURE) through four subsidiaries. Stock Titan | View source ↗ | Stock Titan | Oct 16, 2026 | neutral | 0 | 0.6 |
| UBS Adjusts Price Target on uniQure to $48 From $27, Maintains Buy Rating - Yahoo Finance | UBS Adjusts Price Target on uniQure to $48 From $27, Maintains Buy Rating Yahoo Finance | View source ↗ | Yahoo Finance | Oct 15, 2026 | neutral | 0 | 0.6 |
| uniQure: The Market Graded The Wrong Exam (NASDAQ:QURE) - Seeking Alpha | uniQure: The Market Graded The Wrong Exam (NASDAQ:QURE) Seeking Alpha | View source ↗ | Seeking Alpha | Oct 15, 2026 | neutral | 0 | 0.6 |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ClearPoint Neuro, Inc. - CLPT | Pomerantz LLP is investigating potential securities fraud claims against ClearPoint Neuro following a significant stock price decline. On September 29, 2026, development partner uniQure announced that their joint treatment for Huntington's disease failed to achieve statistical significance on a primary clinical measure at 48 months, causing ClearPoint's stock to plummet 23.12% to $11.77 per share. | View source ↗ | GlobeNewswire Inc. | Oct 13, 2026 | bearish | -1 | 1 |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ClearPoint Neuro, Inc. - CLPT | Pomerantz LLP is investigating potential securities fraud claims against ClearPoint Neuro following a significant stock price decline. On September 29, 2026, development partner uniQure announced that their joint treatment for Huntington's disease failed to achieve statistical significance on a primary clinical measure at 48 months, causing ClearPoint's stock to plummet 23.12% to $11.77 per share. | View source ↗ | GlobeNewswire Inc. | Oct 13, 2026 | bearish | -1 | 1 |
| Why QURE Stock Is Soaring Today? - Stocktwits | Why QURE Stock Is Soaring Today? Stocktwits | View source ↗ | Stocktwits | Oct 12, 2026 | neutral | 0 | 0.6 |
| QURE Stock Just Shot Up 8% - uniQure’s Much-Talked-About Huntington’s Disease Therapy Gets A UK Boost - Stocktwits | QURE Stock Just Shot Up 8% - uniQure’s Much-Talked-About Huntington’s Disease Therapy Gets A UK Boost Stocktwits | View source ↗ | Stocktwits | Oct 9, 2026 | neutral | 0 | 0.6 |
| REPL, QURE Stocks Rise Amid Makary’s Reported Resignation As FDA Chief - Stocktwits | REPL, QURE Stocks Rise Amid Makary’s Reported Resignation As FDA Chief Stocktwits | View source ↗ | Stocktwits | Oct 9, 2026 | neutral | 0 | 0.6 |
| uniQure N.V. (QURE) interactive stock chart – Yahoo Finance - Yahoo Finance Singapore | uniQure N.V. (QURE) interactive stock chart – Yahoo Finance Yahoo Finance Singapore | View source ↗ | Yahoo Finance Singapore | Oct 8, 2026 | neutral | 0 | 0.6 |
| QURE Or RGNX: Which Gene Therapy Was FDA Chief Really Warning About In Rare Disease Remarks? - Stocktwits | QURE Or RGNX: Which Gene Therapy Was FDA Chief Really Warning About In Rare Disease Remarks? Stocktwits | View source ↗ | Stocktwits | Oct 7, 2026 | neutral | 0 | 0.6 |
| uniQure (NasdaqGS:QURE) Stock Forecast & Analyst Predictions - Simply Wall Street | uniQure (NasdaqGS:QURE) Stock Forecast & Analyst Predictions Simply Wall Street | View source ↗ | Simply Wall Street | Oct 2, 2026 | neutral | 0 | 0.6 |
| uniQure (QURE) Faces A Fresh AMT 130 Test After Mixed Data, Bargain Or Trap - Yahoo Finance | uniQure (QURE) Faces A Fresh AMT 130 Test After Mixed Data, Bargain Or Trap Yahoo Finance | View source ↗ | Yahoo Finance | Oct 1, 2026 | neutral | 0 | 0.6 |
| UNIQURE INVESTIGATION: QURE Securities Investors Encouraged to Contact Kirby McInerney LLP About Their Rights | Law firm Kirby McInerney LLP is investigating potential securities law violations by uniQure N.V. following the release of 48-month data for AMT-130 that showed significantly reduced treatment efficacy (44% disease slowing) compared to previously reported 36-month results (75% slowing). The company had submitted an FDA application based on the stronger 36-month data. uniQure's stock price declined 37.3% on the news, falling from $39.11 to $24.51 per share. | View source ↗ | GlobeNewswire Inc. | Sep 30, 2026 | bearish | -1 | 1 |
| QURE Stock Clocks Worst Day In Over 10 Months: Four-Year Huntington’s Data Spooks Investors Despite Stronger Three-Year Filing Data - TradingView | QURE Stock Clocks Worst Day In Over 10 Months: Four-Year Huntington’s Data Spooks Investors Despite Stronger Three-Year Filing Data TradingView | View source ↗ | TradingView | Sep 29, 2026 | neutral | 0 | 0.6 |
| Why Is uniQure Stock Sinking on Tuesday? - Benzinga | Why Is uniQure Stock Sinking on Tuesday? Benzinga | View source ↗ | Benzinga | Sep 29, 2026 | neutral | 0 | 0.6 |
| $QURE stock is down 9% today. Here's what we see in our data. - Quiver Quantitative | $QURE stock is down 9% today. Here's what we see in our data. Quiver Quantitative | View source ↗ | Quiver Quantitative | Sep 24, 2026 | neutral | 0 | 0.6 |
| uniQure (QURE) Stock Could Be Fully Valued As It Files For AMT 130 Approval - Yahoo Finance | uniQure (QURE) Stock Could Be Fully Valued As It Files For AMT 130 Approval Yahoo Finance | View source ↗ | Yahoo Finance | Sep 3, 2026 | neutral | 0 | 0.6 |
| uniQure (QURE) Stock Rises On Cash Runway Despite Deepening Losses - Simply Wall Street | uniQure (QURE) Stock Rises On Cash Runway Despite Deepening Losses Simply Wall Street | View source ↗ | Simply Wall Street | Jul 31, 2026 | neutral | 0 | 0.6 |
| $QURE stock is up 10% today. Here's what we see in our data. - Quiver Quantitative | $QURE stock is up 10% today. Here's what we see in our data. Quiver Quantitative | View source ↗ | Quiver Quantitative | Jul 29, 2026 | neutral | 0 | 0.6 |
| uniQure (QURE) Stock Could Be 49% Undervalued After FDA AMT 130 Update - Yahoo Finance | uniQure (QURE) Stock Could Be 49% Undervalued After FDA AMT 130 Update Yahoo Finance | View source ↗ | Yahoo Finance | Jun 18, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.